PentraSorb® CRP PentraSorb® CRP Adsorber for selective removal of C-Reactive Protein Adsorber for selective removal of C-Reactive Protein Manufacturer: New therapeutic option for Pentracor GmbH Neuendorfstraße 23 b/d Acute myocardial infarction 16761 Hennigsdorf, Germany Stroke Global cerebral ischemia after resuscitation T: D-3302 20944935 F: D-3302 20944999 [email protected] Rheumatoid diseases www.pentracor.de Distributors sign Highly selective CRP removal Highly efficient CRP removal Regenerable system Repeated usage 30 ml adsorber volume Safe and easy to use Dieses Projekt wird durch das Land Brandenburg mit Mitteln der Europäischen Union unterstützt C-Reactive Protein (CRP) CRP, the prototype of an acute-phase reactant, is produced in the liver and primarily serves as a marker of inflammation. The natural ligand for CRP is lysophosphatidylcholine, which is expressed on the surface of bacteria or necrotic and apoptotic cells. Binding of CRP leads to the activation of the complement system via the C1q complex resulting in phagocytosis by macrophages. There is substantial evidence that CRP plays a key role in enlargement of myocardial and cerebral infarction areas.[1] The therapeutic depletion of CRP may lead to both cardioprotection following myocardial infarction[2] as well as neuroprotection after stroke[3]. CRP-Apheresis with PentraSorb® CRP Medical equipment and accessories CRP levels dramatically increase in patients with myocardial infarction beginning 6 hours after the onset of symptoms and peaking at 48-72 hours. For operating the regenerable PentraSorb® CRP adsorber, an apheresis unit provides a suitable application program for all rinsing, loading, regeneration and preservation steps. PentraSorb® CRP adsorbers are provided for the treatment of diseases where reduced CRP levels might prevent further damage. “Therapeutic inhibition of CRP is thus a promising new approach to cardioprotection in acute myocardial infarction, and may also provide neuroprotection in stroke. Potential wider applications include other inflammatory, infective and tissue-damaging conditions characterized by increased CRP production, in which binding of CRP to exposed ligands in damaged cells may lead to complement-mediated exacerbation of tissue injury” Pepys et al., Nature 2006.[1] PentraSorb® CRP For the first time, a fast, selective and efficient reduction of CRP is possible. Reduction in CRP levels with PentraSorb® CRP PentraSorb® CRP is fully regenerable to ensure maximum removal efficiency during therapy. PentraSorb® CRP adsorbers are intended for multiple use in a single patient. CRP level mg/L PentraSorb® CRP is an adsorber for the selective removal of CRP from plasma. During apheresis, CRP is reversibly bound to our adsorbent. Treatment is performed in a number of cycles in which CRP removal and adsorber regeneration alternates. CRP can be reduced by up to 70%. The safety and efficiency of CRP-apheresis with PentraSorb® CRP have been proven in preclinical studies. [2,4] [1] Pepys et al., Nature 2006;440:1217-1221 [2] Sheriff et al., J Clin Apher 2014 [3] Gill et al., J Cereb Blood Flow Metab 2004;24:1214-18 [4] Slagman et al., Blood Purif 2011;31:9-17 Time Such a program is currently available for the ADAsorb®-apheresis system (medicap clinic GmbH, Ulrichstein). For cell separation, a centrifuge or filter system is required, to which the apheresis unit must be adapted. All required disposables for CRP-apheresis are available in treatment sets.
© Copyright 2024 ExpyDoc
